GO
Loading...

Novartis AG

More

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.

  • *Novartis move adds to Big Pharma retreat from antibiotics R&D. ZURICH, Aug 20- Novartis has signed a licensing deal to hand over its experimental tuberculosis drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

  • NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.

  • NEW YORK,- A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

  • NEW YORK, Aug 7- A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

  • SAN FRANCISCO, Aug 5- The Netherlands' Royal Philips and IT consultancy Accenture are developing software to help people with neurodegenerative diseases like amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease, live more independently. Accenture and Philips jointly developed the software that connects the various technologies.

  • The Senate Judiciary Committee's nine-member antitrust panel will meet on Wednesday to consider the decisions by Alcon, owned by Novartis AG; Bausch& Lomb, owned by Valeant Pharmaceuticals; and Johnson& Johnson to put in place minimum sale prices for some of their products.

  • The Senate Judiciary Committee's nine-member antitrust panel will meet on Wednesday to consider the decisions by Alcon, owned by Novartis AG; Bausch+ Lomb, owned by Valeant Pharmaceuticals; and Johnson& Johnson to put in place minimum sale prices for some of their products.

  • BASEL, July 24- Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.

  • U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • UPDATE 2-GSK warns on profits as weak lung drug sales hit Wednesday, 23 Jul 2014 | 9:12 AM ET

    LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • Weak lung drug sales and strong pound hit GlaxoSmithKline Wednesday, 23 Jul 2014 | 7:11 AM ET

    LONDON, July 23- GlaxoSmithKline's sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • LONDON, July 22- European shares bounced back on Tuesday on some strong earnings reports and after signs of cooperation between Russia and other nations in investigating the shooting down of a Malaysian airliner over Ukraine.

  • European shares bounce back as Ukraine tension ease Tuesday, 22 Jul 2014 | 11:25 AM ET

    LONDON, July 22- European shares rose on Tuesday on some strong earnings reports and signs of improved cooperation from Ukraine's pro-Russian rebels over the Malaysian Airlines plane shot down four days ago.

  • LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.

  • *ARM Holdings surges after strong results. LONDON, July 22- European equities bounced back on Tuesday partly in response to signs of improved cooperation from Ukraine's pro-Russian rebels who have agreed to hand over the black boxes from the Malaysian plane downed in Ukraine last week.